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ABSTRACT
Using RT and amplification, we have detected specific RNA tran-
scripts encoding somatostatin in FRTL-5 thyroid cells. This observa-
tion indicates that within the thyroid context, expression of soma-
tostatin is not restricted to the parafollicular C cells. Transfection of
FRTL-5 cells with constructs containing either the complete soma-
tostatin gene promoter or deletions carrying the cAMP response
element-binding site allowed us to demonstrate that transcription of
the somatostatin gene is hormonally regulated by TSH. Blockage of
somatostatin by specific antibodies resulted in an increased capacity
of TSH-induced FRTL-5 cell-conditioned medium to promote cell pro-
liferation, demonstrating that under physiological conditions, soma-
tostatin exerts a cytostatic effect on FRTL-5 cells growth. Somatosta-
tin treatment of FRTL-5 cells resulted in a growth retardation, caused
by a dose-response delay in the G1 phase of the cell cycle. This effect
appears to be mediated by the cyclin-dependent kinase inhibitor
p27kip1, which is clearly down-regulated in FRTL-5 cells treated with
TSH and whose expression is reestablished by somatostatin in a
dose-dependent manner. Participation of somatostatin in the control
of FRTL-5 cell proliferation is in agreement with the detection of
specific somatostatin receptor type 2. Flow cytometric assays reveal
that FRTL-5 cells transformed with the K-ras oncogene are still sen-
sitive to somatostatin treatment, whereas fully neoplastic FRT cells
no longer respond to this peptide. Taking together, the results dem-
onstrate the participation of an autocrine loop in the control of thyroid
cell proliferation, and the possibility that this mechanism could be
altered in the process of thyroid carcinogenesis. (Endocrinology 140:
87–95, 1999)
THE PRECISE control of cell proliferation requires thebalance between positive effectors of cell growth and
cytostatic signals that allow the maintenance of the differ-
entiated phenotype. In the follicular thyroid cell, the transi-
tion from quiescent to proliferating cells is mainly mediated
by the actions of TSH and insulin-like growth factor I (IGF-I)
(1, 2) and involves the activity of the tissue-specific tran-
scription factors TTF-1 and Pax-8 (3). Less is known about the
antimitogenic signals affecting thyroid cell proliferation.
Somatostatin was initially identified as a potent GH in-
hibitor in the hypothalamus and soon after was found in
many tissues and cell lines, exerting different biological ac-
tions, including inhibition of hormone secretion processes,
modulation of cardiovascular activity, control of neural cog-
nitive and locomotor functions, and regulation of cell pro-
liferation (4, 5). Immunoreactive somatostatin has also been
found in the thyroid, more precisely limited to the parafol-
licular C cells, leading to the speculation that this peptide
could elicit local effects on thyroid hormone release acting
locally, in a paracrine fashion (6). In the differentiated thy-
roid cell line FRTL-5, somatostatin inhibits TSH- and IGF-I-
mediated cell proliferation (7). More recently, the effect of
somatostatin on cell proliferation has also been characterized
in the thyroid cell line PC Cl3. In these cells, somatostatin is
able to inhibit insulin-dependent and insulin-plus TSH-de-
pendent cell growth, causing a delay block in the G1-S tran-
sition of the cell cycle (8).
Somatostatin action is mediated by specific receptors, and
to date, six different subtypes (designated SSTR-1, -2A, -2B,
-3, -4, and -5) have been cloned and functionally character-
ized in various cell systems, including pancreas, adrenal
cortex, and brain tissue (9). They belong to the seven-trans-
membrane domain superfamily and are coupled to different
G proteins that link SSTR to distinct cellular effector systems,
such as adenyl cyclase, K1, and Ca21 channels. Different
receptors may regulate a variety of cellular functions, thus
providing a broad spectrum of somatostatin action. SSTR2
along with SSTR1 and -5 are responsible for the antiprolif-
erative effect of somatostatin and are expressed in many
tumor types (10, 11). Currently, the design of synthetic so-
matostatin analogs with high affinity for these SSTR is a
clinical approach for a variety of tumor diseases.
Several reports indicate that the mechanisms responsible
for the antiproliferative effect of somatostatin are related to
its ability to modulate phosphotyrosine phosphatase activity
(8, 10, 12, 13). In this study we show that somatostatin action
is mediated by the cyclin-dependent kinase inhibitor p27kip1.
This protein, initially identified by the ability to bind the
complexes cyclin E-cyclin-dependent kinase-2 (cyclin
E-CDK2) (14) and cyclin D-CDK4 (15), belongs to the Cip/
Kip family of CDK inhibitors and plays a critical role in the
regulation of G1-S transition (16).
In this report we provide evidence that somatostatin is
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expressed in FRTL-5 cells. Furthermore, transcription of the
somatostatin gene is under hormonal control exerted by
TSH, as determined by transient transfection assays. Exper-
iments with conditioned medium from TSH-treated FRTL-5
cells and somatostatin antibodies revealed that this peptide
exerts a cytostatic effect on cell growth. This circumstance is
further supported by cytometric assays, showing that soma-
tostatin blocks FRTL-5 cell cycle in the G1 phase. As men-
tioned above, we demonstrate that this effect is mediated by
the capacity of somatostatin to reestablish the expression of
the CDK inhibitor p27kip1, which is down-regulated by TSH
to promote proliferative signals. In thyroid tumor and trans-
formed cells, the ability of somatostatin to modulate cell
growth is altered. The results suggest that within the thyroid
follicular cell, somatostatin expression is used as a precise,
local mechanism to regulate cell growth in an autocrine
fashion.
Materials and Methods
Cell culture and somatostatin treatment
FRTL-5 thyroid cells (17) (American Type Culture Collection, Man-
assas, VA; CRL 8305) were grown in Coon’s modified Ham’s F-12 me-
dium (Sigma Chemical Co.) supplemented with 5% donor calf serum
(Life Technologies, Gaithersburg, MD) and a hormone mixture includ-
ing 10 ng/ml glycyl-l-histidyl-l-lysine, 5 mg/ml transferrin, 10 nm hy-
drocortisone, 10 ng/ml somatostatin, 10 mg/ml insulin, and 1 nm TSH.
K-ras-transformed FRTL-5 (18) and the thyroid tumor cell line FRT (19)
cells were maintained in the same conditions. All of the hormones were
purchased from Sigma Chemical Co. (St. Louis, MO). The human thyroid
carcinoma cell line ARO (20), the rat pancreatic-derived cell line RIN
(21), and the human medullary carcinoma cell line MTT (22) were grown
in RPMI 1640 medium supplemented with 10% FCS, 2 mm glutamine,
100 mg/ml sodium pyruvate, and antibiotics. Before treatment, cell
cultures were maintained for 72 h in a 3H medium (basal Coon’s sup-
plemented with 0.2% FCS without insulin, TSH, and somatostatin).
RT-PCR amplification
Total RNA was isolated as previously described (23). For first strand
complementary DNA synthesis, total RNA (1 mg) was treated with
deoxyribonuclease and reversely transcribed at 42 C for 30 min using
Moloney murine leukemia virus reverse transcriptase (Pharmacia Bio-
tech, Piscataway, NJ). Aliquots of the first strand reactions (10 ml) were
used as templates for subsequent PCR using Taq polymerase (Perkin-
Elmer, Norwalk, CT). For detection of somatostatin transcripts, the
following primers were used: forward, 59-CAGACTCCGTCAGTTTCT-
GCA-39; and reverse, 59-GCTAACAGGATGTGAATGTC-39. Amplifica-
tion was performed in 35 cycles of 30 sec (2 min for the first cycle) at 95
C, 30 s at 55 C, and 1 min at 72 C (5 min for the last cycle). For the different
somatostatin receptors (24–27), the primers for forward and reverse
annealing were: SSTR-1, 59-GCTACGTGCTCATCATTGCTA-39 and 59-
GGACTCCAGGTTCTCAGGTTC-39; SSTR-2, 59-TTGGTACACAG-
GGTTCACAT-39 and 59-GTCTCCGTGGTCTCATT CAGC-39; SSTR-3,
59-TCATCTGCCTCTGCT ACCTA-39 and 59-GAGCCCAAAGAAG-
GCAGGCT-39; SSTR-4, 59-ATCTTCGCA GACACCAGACC-39 and 59-
ATCAAGGCTGGTCACGACGA-39; and SSTR-5, 59-GCCGGCCTC-
TACTTCTTCGTG-39 and 59-CCGTGGCGTCAGCGTCCTTGG-39. Con-
ditions for PCR have been recently described (28). PCR products were
visualized in 2% agarose gels, and the identities of positive bands were
confirmed by direct sequencing of the PCR products (automated DNA
sequencer, Applied Biosystems, Foster City, CA).
Plasmids and transfections
The reporter construct containing the complete somatostatin gene
promoter (SMS900), deleted constructs containing the cAMP response
element (CRE)-binding site with or without the upstream enhancer
promoter (SMS120 and SMS65, respectively), and the construct contain-
ing the region of the TATA box (SMS42) have been used in this study
and were described previously (29). These constructs were transiently
transfected by the calcium phosphate precipitation technique (30) into
confluent FRTL-5 cells and then maintained in basal medium (3H) or
treated for 24 h with 1 nm TSH. The plasmid CMV-Luc was used to
correct for transfection efficiency. Forty-eight hours after transfection,
cell extracts were prepared, and chloramphenicol acetyl transferase and
luciferase activities were determined (30, 31).
Cell proliferation and flow cytometric analysis
Conditioned medium from FRTL-5 cells maintained in basal condi-
tions (3H) and treated with TSH (3H1TSH) was collected after 72 h for
functional assays. The mitogenic activity of the medium was tested on
quiescent FRTL-5, by cell counting after 24, 48, and 72 h. To test any
potential role of somatostatin, this conditioned medium was preincu-
bated with a specific somatostatin antibody (4 mg/ml) (32) for 1 h at room
temperature before addition to the FRTL-5 cultures. Growth curves in
the presence of increasing concentrations of somatostatin were also
performed. FRTL-5 cells (2 3 104) were maintained in basal medium for
72 h and then treated with 1 nm TSH, somatostatin, or TSH plus so-
matostatin (10 nm, 1 mm, and 2 mm). The number of viable cells was
determined by cell counting every 24 h for 4 consecutive days, and the
average of three independent experiments is represented. Cell cycle
distribution from propidium iodide-stained samples was performed as
previously described (33), using a FACScan flow cytometer (Becton
Dickinson Co., Mountain View, CA). At least 10,000 events were col-
lected and analyzed. Data were integrated and plotted with the software
CellQuest.
Immunoblotting analysis
Total protein extracts (40 mg) were subjected to SDS-PAGE. Proteins
were transferred to nitrocellulose membranes (Schleicher & Schuell, Inc.,
Keene, NH) in a buffer containing 25 mm Tris, 200 mm glycine, and 20%
methanol. After blocking the membranes with 10% low fat dried milk
in Tris-buffered saline containing 0.05% Tween-20, immunodetection
was performed using 5 mg/ml of a commercial antibody for p27kip1 and
cyclin D1 (Oncogene Science, Inc., Cambridge, MA). After probing with
the antibodies, membranes were incubated with a streptavidin-conju-
gated antirabbit specific secondary antibody. Immunoreactive bands
were visualized by enhanced chemiluminiscence (Amersham, Arlington
Heights, IL). To assess equal loading of the samples, the same blots were
reprobed with a specific antiactin antibody (Calbiochem, La Jolla, CA).
Statistical analysis
Statistical significance between different treatments was determined
using Student’s t test. Differences are considered significant at P , 0.05.
Results
Somatostatin- and SSTR2-specific transcripts are detected
in thyroid FRTL-5 cells
In search of regulatory mechanisms responsible for the
control of thyroid cell proliferation, we evaluated whether
somatostatin could be expressed and secreted by the follic-
ular thyroid cell in an autocrine fashion. To address this
question, we isolated total RNA from FRTL-5 cells and per-
formed RT-PCR reactions in the conditions described in Ma-
terials and Methods. Forward primer was designed from exon
1 sequences, whereas reverse primer was located in exon 2.
This way, any potential contamination of DNA would render
a larger PCR fragment containing intronic sequences. PCR
reactions were resolved in agarose gels and in these condi-
tions, a 271-bp DNA band was reproducibly amplified from
FRTL-5 retrotranscribed RNA (Fig. 1A). In control experi-
ments, the same band was obtained from RNA samples
extracted from the human medullary carcinoma cell line
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MTT and the rat pancreas-derived cell line RIN, whereas in
agreement with previous reports (34, 35), somatostatin tran-
scripts were absent in RNA extracted from liver tissue. The
integrity of the RNA preparations was confirmed with spe-
cific primers for b-actin (Fig. 1A). To further assure that
amplified DNA contained somatostatin related sequences,
the 271-bp PCR product was purified and subjected to direct
DNA sequencing. The nucleotide sequence obtained was
identical to that previously described for the rat somatostatin
gene (36).
The results unambiguously demonstrate that somatostatin
transcripts are expressed in FRTL-5 cells, so we next deter-
mined the presence of specific somatostatin receptors. Spe-
cific pairs of primers for SSTR-1, -2, -3, -4, and -5 were used
in RT-PCR reactions. The assay revealed that FRTL-5 cells
exclusively express SSTR-2 (Fig. 1B), failing to detect the
expression of SSTR-1, -3, -4, and -5. We also observed ex-
pression of SSTR-2 in MTT cells, RIN cells, and the human
thyroid carcinoma cell line ARO, which also expressed
SSTR-1. Positive amplification of SSTR-3, SSTR-4, and
SSTR-5 was found in the human medullary carcinoma cell
line MTT.
Transcription of the somatostatin gene in FRTL-5 cells is
hormonally regulated by TSH
The detection of somatostatin transcripts in FRTL-5 cells
prompted us to analyze whether transcription of this gene is
hormonally regulated by TSH, one of the major inductors of
thyroid cell proliferation. Due to the low levels of soma-
tostatin produced by FRTL-5 cells and the difficulty in de-
termining precisely by RT-PCR messenger RNA variations in
response to TSH, an indirect transfection approach was used.
For that purpose, we determined the ability of TSH to pro-
mote transcription of a reporter construct containing the
complete somatostatin gene promoter (designated SMS900).
Also, considering that somatostatin expression in other cell
systems is mainly controlled at the transcriptional level by
CRE (29), the participation of CRE in TSH-mediated soma-
tostatin gene expression was evaluated by using deletion
constructs carrying a CRE-binding site with or without the
upstream enhancer element (SMS120 and SMS65, respec-
tively). These constructs, along with a negative TATA control
vector (SMS42) were transiently transfected in FRTL-5 cells,
using the plasmid CMV-Luc to correct for transfection effi-
ciency. After transfection, cells were maintained in 3H me-
dium and then treated with TSH for 24 h. Control assays
without TSH were carried out in parallel. Results showed a
significant increase in transcription activity from the com-
plete somatostatin promoter (SMS900) in the presence of TSH
(Fig. 2). To a minor extent, transcription was also increased
with the SMS120 construct, whereas SMS65, which contains
a unique CRE-binding site, yielded a weak activation of gene
transcription. When the same set of experiments were per-
formed in the presence of the cAMP analog forskolin, we
FIG. 1. Detection of somatostatin and SSTR2-specific transcripts in
FRTL-5 cells. A, Total RNA extracted from rat liver and FRTL-5,
MTT, and RIN cells was subjected to RT and amplification using
specific primers for somatostatin. To assess the integrity of the RNA
preparations, b-actin was amplified from the same samples. B, De-
tection of different SSTRs from ARO, FRTL-5, MTT, and RIN cells
was also performed by RT and amplification. PCR products were
resolved by electrophoresis, and DNA fragments were visualized in
agarose gels stained with ethidium bromide. The sizes of the PCR
fragments are indicated.
FIG. 2. Transcription of somatostatin in FRTL-5 cells is regulated by
TSH. Equal numbers of cells (2 3 106) were transfected with reporter
construct containing the complete somatostatin promoter (SMS900)
or deletions containing a CRE element with or without the upstream
enhancer element (SMS120 and SMS65, respectively). A control vec-
tor containing the TATA box (SMS42) was also used. Plates were then
treated with either TSH (1029 U/ml) or forskolin (10 mg/ml) for 24 h.
Induction of the somatostatin gene was determined as percentage of
acetylation. Values were corrected for transfection efficiency with
luciferase activity. Values represent the average of three independent
experiments. *, Significant differences vs. 3H (P , 0.01).
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found a similar patter of induction of gene transcription. The
results demonstrated that the somatostatin gene promoter is
functional in FRTL-5 cells, and although moderate, its ex-
pression is positively regulated by TSH through the cAMP
signaling pathway.
Biological effects of somatostatin expression in FRTL-5 cells
The detection of somatostatin transcripts, the presence of
somatostatin receptors, and the fact that transcription of the
gene is positively regulated by TSH prompted us to analyze
whether an autocrine loop of somatostatin could be func-
tionally established in FRTL-5 cells. The contribution of au-
tocrine production of somatostatin to FRTL-5 cell growth
was analyzed by testing the mitogenic activity of the con-
ditioned medium from cells maintained in basal medium
(3H) and treated with TSH (3H1TSH), where expression of
somatostatin should be induced. Conditioned medium was
collected and added to quiescent FRTL-5 cells, and cell num-
ber was determined after 24, 48, and 72 h. Results are sum-
marized in Table 1. 3H-conditioned medium did not have
any significant effect on FRTL-5 cell growth. As expected,
conditioned medium from TSH-stimulated FRTL-5 clearly
induced cell proliferation due to the presence of TSH in the
conditioned medium. These effects were evident after 24 h of
the addition of conditioned medium.
To search for any specific effect mediated by somatostatin,
presumably produced by FRTL-5 after TSH stimulation, con-
ditioned medium from TSH-stimulated cells was preincu-
bated with an antisomatostatin antibody (32) before the ad-
dition to quiescent FRTL-5 cells. Cell number was also
determined at the same time points (24, 48, and 72 h), and cell
number was determined. Although no significant differences
were found after 24 and 48 h, cell number was always higher
when somatostatin was specifically blocked from the FRTL-5
culture medium. These results were significant after 72 h and
indicate that although other growth factors secreted by TSH-
induced cells could mask somatostatin action, this peptide
exerts a cytostatic effect on FRTL-5 cell growth. When the
same set of experiments was performed in the presence of an
irrelevant IgG instead of the somatostatin antibodies, cell
number was similar to that obtained with 3H1TSH-condi-
tioned medium (data not shown).
Somatostatin exerts an inhibitory effect of TSH-mediated
cell proliferation resulting in cellular accumulation in the
G1 phase of the cell cycle
After demonstrating a biological role for somatostatin in
the FRTL-5 conditioned medium, the effects of the peptide on
cell growth and cell cycle distribution were analyzed in more
detail. Growth curve profiles of depleted cells treated with
TSH (1 nm), somatostatin, and the combination of TSH and
somatostatin (10 nm, 1 mm, and 2 mm) were determined every
24 h for 4 consecutive days. Control cells maintained in 3H
medium were also included in the assay (Fig. 3). In the latter,
the number of viable cells remained unaltered throughout
the assay. TSH rapidly increased cell number, with the in-
duction of cell proliferation more evident within the first 24 h
of TSH exposure. To a minor extent, proliferation was de-
tected up to 72 h. When TSH was added in combination with
somatostatin, a detectable inhibition of cell proliferation was
observed even at a dose of 10 nm. Higher concentrations of
somatostatin increased growth inhibition, and at 1 mm, re-
duction of TSH-induced proliferation was nearly 40% after
24 h. Similar results were obtained at 2 mm, suggesting that
although the cellular response is dose dependent, a partial
desensitization in response to somatostatin is observed at
high doses. It is important to remark that whereas cell num-
ber stabilized after 72 h of TSH treatment, the presence of
somatostatin in the medium decreased cell viability after 3
days in culture. We also found that somatostatin requires the
presence of the positive effector to alter cell proliferation, as
in the absence of TSH, somatostatin did not exert any effect
on FRTL-5 cell growth, demonstrating the connection be-
tween somatostatin and TSH signaling pathways.
Cell cycle distribution in the same experimental conditions
were performed by flow cytometric assays from propidium
iodide-stained samples (Fig. 4). Cells maintained in 3H me-
dium for 72 h were stimulated with TSH and treated with
different concentrations of somatostatin. After 16 and 24 h,
samples were collected, fixed in ethanol, and stained with
propidium iodide for cell cycle analysis. Results are sum-
marized in Table 2. Cell cycle distribution of 3H cells re-
mained unaltered throughout the assay, with S phase values
approximately 4% and G2-M values 16% of the total cell
population. It is important to mention that although these
values seem to indicate cellular transit through the cell cycle,
growth curves indicate that FRTL-5 cells do not proliferate
under these conditions (Fig. 3). As it will be discussed below,
TABLE 1. Effect of FRTL-5 conditioned medium on cell growth
Cell no. (3104)
24 h 48 h 72 h
Basal (3H) 38.7 6 3.2 40.75 6 10.1 51 6 14.3
1TSH 84.8 6 4.3 100.37 6 13.1 125.1 6 19.1
1TSH 1 anti-SS 88.2 6 3.9 106.75 6 12.7 189.6 6 18.2a
Cells were maintained in 3H for 96 h, conditioned medium was
collected and added to depleted FRTL-5 cells in culture (2 3 105
cells/dish). Viable cell number was then determined after 24, 48, and
72 h. Somatostatin antibody was used at a dilution of 4 mg/ml.
a P , 0.01 vs. 3H 1 TSH.
FIG. 3. Effect of somatostatin on TSH-mediated cell proliferation.
Cells maintained in basal medium for 72 h were treated with soma-
tostatin and TSH alone or in combination. Cell number was monitored
every 24 h for 4 consecutive days, and viable cell number is repre-
sented. The data are the mean 6 SD of three independent experiments.
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we believe that this circumstance could be due to the absence
of somatostatin and the presence of 0.2% serum in the basal
medium. TSH treatment of depleted FRTL-5 cells clearly
promoted G1 transition to S phase, reaching maximum ac-
cumulation in G2-M (42.8%) after 24 h. However, when the
cells were treated with TSH and somatostatin, a dose-
dependent accumulation in G1 was detected, and at 2 mm, cell
cycle profiles were similar to those obtained in cells main-
tained in 3H medium (Fig. 4).
Effect of somatostatin on cell cycle correlate with the ability
to prevent TSH-mediated down-regulation of p27kip1
To examine the mechanisms responsible for growth inhi-
bition induced by somatostatin, and more precisely the G1
block detected by flow cytometry, we investigated cell cycle-
related genes that could be mediating somatostatin action. As
the CDK-dependent kinase inhibitor p27kip1 is one of the
major regulators of the G1-S transition, we analyzed the effect
of TSH on p27kip1 protein levels by Western blot in the ab-
sence or presence of somatostatin (Fig. 5). The results dem-
onstrate that the ability of TSH to promote cell proliferation
is associated with a strong inhibitory effect on p27kip1, which
becomes undetectable after 24 h of TSH treatment. Soma-
tostatin was able to block TSH-mediated down-regulation of
p27kip1, returning protein levels to almost those levels ob-
served in quiescent cells. The effect was dose dependent, and
as shown in Fig. 5B, increasing the concentration of soma-
tostatin resulted in higher levels of p27kip1 protein. The re-
sults are in agreement with flow cytometric profiles, indi-
cating that maximum G1 arrest is achieved at a 2-mm dose of
somatostatin. These results were already evident after 16 h
of TSH treatment and extended up to 36 h (not shown).
To further confirm that the effect on p27kip1 protein levels
was specifically modulated by somatostatin, we analyzed
other cell cycle regulatory genes that are also involved in the
G1-S transition. We reasoned that if somatostatin specifically
targets the G1 phase of the cell cycle acting through p27, other
cell cycle regulatory proteins important for the G1-S transi-
FIG. 4. Effect of somatostatin treatment on cell cycle distribution of FRTL-5 cells. Flow cytometric histograms of FRTL-5 cells maintained in
3H medium for 72 h, stimulated with TSH, and treated with different concentrations of somatostatin are represented. Samples were collected
after 24 h of treatment for FACS analysis. The intensity of the propidium iodide staining vs. cell number is represented. The percentage of the
cell cycle distribution is shown in Table 2.
TABLE 2. Cell cycle progression of FRTL-5 cells stimulated with TSH and treated with different concentrations of somatostatin
16 h 24 h
G0/G1 S G2/M G0/G1 S G2/M
3H 79.9 6 1.5 4.1 6 0.08 16.0 6 0.16 78.9 6 0.08 4.0 6 0.08 17.1 6 0.08
1TSH 76.7 6 0.16 3.4 6 0.08 19.9 6 0.21 51.0 6 0.24 6.2 6 0.08 42.8 6 0.24
1TSH 1 SS (10 nM) 74.9 6 0.16 7.8 6 0.16 17.3 6 0.24 65.5 6 0.16a 4.4 6 0.16 30.1 6 0.16
1TSH 1 SS (1 mM) 78.6 6 0.32 4.3 6 0.08 17.1 6 0.16 77.7 6 0.24a 5.6 6 0.17 16.7 6 0.24
1TSH 1 SS (2 mM) 77.1 6 0.16 4.6 6 0.09 18.3 6 0.16 80.5 6 0.4a 3.8 6 0.16 15.7 6 0.26
Samples were collected after 16 h and 24 h of TSH with or without somatostatin treatment, and cell cycle was analyzed by FACScan. Values
are expressed as percentages.
a P , 0.01 vs. 3H 1 TSH.
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tion, such as cyclin D1, would not be modulated by soma-
tostatin. As expected, TSH treatment of quiescent cells in-
creased protein levels of cyclin D1 (37), but in this case,
somatostatin is not able to down-regulate cyclin D1 (Fig. 5A).
This observation indicated that rather than decreasing the
activity of the cyclin-CDK complexes, somatostatin causes
cell cycle delay by increasing the level of the CDK inhibitor
p27kip1.
The ability of somatostatin to modulate cell growth is
altered in transformed and tumor thyroid cells
The results presented indicate that somatostatin, secreted
by FRTL-5 cells and acting through an autocrine loop, reg-
ulates thyroid cell growth. We analyze whether this potential
regulatory pathway could be altered in the process of thyroid
carcinogenesis, testing the cellular response to somatostatin
in a transformed cell line (K-ras-FRTL-5) and a tumor-
derived cell line (FRT). First, we analyzed whether these
transformed and tumor cells express somatostatin receptors
that could mediate a potential response to somatostatin. RT-
PCR analysis reveals that as observed for FRTL-5 cells, K-ras-
FRTL-5 cells and FRT cells express SSTR-2 receptor (Fig. 6).
We next determined the ability of somatostatin to modu-
late cell cycle in these cell lines. Because both cell lines are
independent of TSH, quiescent cells were treated with serum
in the present or absence of somatostatin. Results (Fig. 7)
showed that K-ras-FRTL-5 cells are still sensitive to soma-
tostatin, although higher doses (2 mm) are required to obtain
a detectable increment in G1 phase. Any dose over 2 mm did
not result in greater inhibition of cell proliferation (Table 3).
We also detected the presence of hypodiploid cells, presum-
ably undergoing apoptosis, which are absent in control cells
and FRTL-5 cells, although this observation requires further
analysis. However, fully neoplastic thyroid FRT cells were no
longer sensitive to somatostatin, as cell cycle distribution
remained unchanged in the absence or presence of somato-
statin.
The possibility that the regulatory mechanism mediated
by p27kip1 in differentiated thyroid cells could be also re-
sponsible for the cell cycle delay in K-ras-FRTL-5 was then
analyzed. By Western analysis, we determined that K-ras-
FRTL-5 express p27kip1 in the absence of serum (Fig. 8).
Unlike the addition of TSH to normal FRTL-5 cells, serum did
not result in any significant decrease in p27kip1. When serum-
treated cells were exposed to somatostatin, p27kip1 levels
recovered, although these results were not significant either.
These results indicate that in these transformed cells, the
effect of somatostatin is rather weak, presumably indicating
that within the process of carcinogenesis, the loss of soma-
tostatin sensitivity is a late event and drives cells to a more
undifferentiated status.
Discussion
The results presented in this paper provide strong evi-
dence that somatostatin, produced by the differentiated thy-
roid cell and acting locally, may be responsible for a precise
regulation of cell proliferation. The detection of somatostatin
transcripts by means of PCR amplification in follicular thy-
roid cells revises classic studies in which expression of this
peptide in the thyroid is limited to the parafollicular C cells
(6) and suggest novel mechanisms of autocrine regulation of
thyroid cell growth. This study also confirms previous ob-
servations that although somatostatin is mainly produced by
central nervous structures and pancreatic cells (34), other
sources may be found. In particular, in organs such as the
pineal gland, a dual origin (neural and parenchymal) of
somatostatin has been demonstrated (35).
Regulation of somatostatin transcription by TSH is spe-
cially relevant in FRTL-5 cells. First, it is important to remark
that somatostatin expression is increased when FRTL-5 cells
are treated with TSH. Second, the results obtained in our
FIG. 5. Somatostatin prevents TSH-mediated down-regulation of the
CDK-dependent inhibitor p27kip1. A, FRTL-5 protein extracts from
depleted (3H), somatostatin (3H1SS), and TSH-stimulated without
(3H1TSH) or with somatostatin (3H1TSH1SS) were probed with
specific antibodies for p27kip1, cyclin D1, and actin. B, Dose response
of p27kip1 protein levels. Depleted FRTL-5 cells were treated with
TSH in the absence or presence of increasing concentration of soma-
tostatin for 24 h. After treatment, proteins were extracted and probed
with a p27kip1 antibody and revealed by chemiluminiscence.
FIG. 6. Detection of SSTR-2 in transformed K-ras-FRTL-5 and tumor
FRT cells. Total RNA was subjected to RT and amplification using
specific primers for SSTR-2. PCR products were resolved by electro-
phoresis, and DNA fragments were visualized in agarose gels stained
with ethidium bromide. b-Actin was amplified from the same sam-
ples. For the control reaction, the same RT and PCR reactions were
performed in the absence of RNA. The sizes of the PCR fragments are
indicated.
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transfection assays indicate that the somatostatin promoter
is functional and positively regulated by TSH. The fact that
a positive effector of cell growth such as TSH promotes
transcription of an antiproliferative peptide is physiologi-
cally important, because the interaction and balance between
both signals may be responsible for the precise growth rate
of the thyroid cell. Somatostatin gene transcription has been
well characterized in the pancreatic RIN cells (29, 38) and has
been demonstrated to be mainly controlled at the transcrip-
tional level by CRE, which is recognized by the CREB and
several other nuclear proteins (36). In these cells, a CRE site
and another element, designated UE (upstream enhancer),
cooperate synergistically to promote transcription, and
therefore, a deleted construct of the somatostatin promoter
containing these two elements confers maximum activity to
reporter constructs in the presence of cAMP activators (29,
38). With respect to FRTL-5 cells, we demonstrated that the
somatostatin promoter is functional, and therefore, all the
regulatory elements necessary for the transcription of this
gene are present within these thyroid cells. It would be of
interest to analyze which transcription factor(s) is involved
in the control of somatostatin gene transcription and whether
thyroid-specific transcription factors (39) play any role in this
process.
It is generally accepted that TSH and IGF-I synergize to
stimulate thyroid cell proliferation (1, 2). Whether TSH is
sufficient to promote cell proliferation of FRTL-5 cells may
depend on the culture conditions (37, 40). In our experiments,
the addition of TSH to cells maintained in 3H medium clearly
induces cell proliferation. The explanation for this different
response of FRTL-5 cells to TSH may lie in the absence or
presence of somatostatin. This peptide is routinely added to
the FRTL-5 culture medium (17, 41, 42), whereas it is absent
in our control assays. Somatostatin may be sufficient to keep
cells arrested, and our cell cycle profiles in the absence or
presence of somatostatin also support the idea that this pep-
tide is a critical regulator of thyroid cell proliferation. These
results are further supported by the fact that somatostatin,
secreted by FRTL-5 cells in the presence of TSH, exert a
cytostatic effect on thyroid cell growth.
The results presented indicate that the control of cell cycle
regulation exerted by somatostatin specifically targets the G1
FIG. 7. Sensitivity of transformed and tumor cells to somatostatin. Exponentially growing rat thyroid carcinoma cells FRT and K-ras-
transformed FRTL-5 cells were treated with 2 mM somatostatin for 24 h, and cell cycle distribution was analyzed (right panels). Untreated cells
were used as a control (left panels). The percentage of the cell cycle distribution is shown in Table 3. The presence of hypodiploid nuclei after
somatostatin treatment of K-ras-transformed FRTL-5 is shown by an arrow.
TABLE 3. Cell cycle progression of K-ras-FRTL-5 and FRT cells treated with different concentrations of somatostatin
K-ras-FRTL-5 FRT
G0/G1 S G2/M G0/G1 S G2/M
Control 56.9 6 0.08 24.7 6 1.5 18.4 6 0.48 50.7 6 0.5 28.5 6 0.48 20.8 6 0.57
1SS (10 nM) 58.0 6 0.8 24.4 6 0.6 17.6 6 0.58 52.9 6 0.53 25.9 6 1.63 21.1 6 0.73
1SS (1 mM) 58.3 6 0.4 24.6 6 0.7 17.1 6 0.97 54.0 6 1.22 23.5 6 0.5 22.5 6 0.4
1SS (2 mM) 68.3 6 1.14a 20.3 6 1.3 11.4 6 1.12 50.1 6 0.27 22.5 6 3.2 27.4 6 1.87
Samples were collected after 24 h of TSH with or without somatostatin treatment, and cell cycle was analyzed by FACScan. Values are
expressed as percentages.
a P , 0.01 vs. control.
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phase of the cell cycle. As described previously (43, 44), we
also show that proliferative signals induced by TSH are as-
sociated with a down-regulation of the cyclin-dependent
kinase inhibitor p27kip1. This down-regulation is prevented
by somatostatin, which returns p27kip1 protein levels to those
observed in quiescent cells. Two pieces of evidence support
the idea that this effect is specific rather than a consequence
of differences in cell growth. First, the effect is dose depen-
dent, and second, other cell cycle regulatory proteins im-
portant for G1-S transition, such as cyclin D1, are not mod-
ified by somatostatin treatment. In this context, our results
are in agreement with the description that TSH is able to
up-regulate the expression of cyclin D1 (37) to favor cell
proliferation. We are currently investigating possible links
between changes in cell cycle and changes in tyrosine phos-
phatase activity, which is also mediated by somatostatin, as
previously described in the literature (8, 10).
Our results indicate that the ability of some transformed
and tumor thyroid cell lines to respond to somatostatin is
altered. Moreover, as many of these cell lines proliferate
independently of TSH, the idea that somatostatin requires
the positive effect induced by TSH to modulate cell growth
is further supported. Our observations are in agreement with
those previously reported (8) showing that differentiated
PC-Cl3 thyroid cells turned insensitive to somatostatin when
transformed with the E1a oncogene. These cells retain the
expression of SSTR4 (8), and in our assays we have detected
the expression of SSTR2 in both FRT and K-ras-FRTL-5 cells.
These data indicate that the expression of somatostatin re-
ceptors does not directly correlate with the capacity of a
given cell line to respond to somatostatin. Rather, some other
intracellular mechanism, currently under investigation, is
responsible for the interference with the somatostatin effect
in thyroid transformed and tumor cells.
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